BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

505 related articles for article (PubMed ID: 20139156)

  • 1. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE).
    Garcia-Carbonero R; Capdevila J; Crespo-Herrero G; Díaz-Pérez JA; Martínez Del Prado MP; Alonso Orduña V; Sevilla-García I; Villabona-Artero C; Beguiristain-Gómez A; Llanos-Muñoz M; Marazuela M; Alvarez-Escola C; Castellano D; Vilar E; Jiménez-Fonseca P; Teulé A; Sastre-Valera J; Benavent-Viñuelas M; Monleon A; Salazar R
    Ann Oncol; 2010 Sep; 21(9):1794-1803. PubMed ID: 20139156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trends in diagnosis of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in India: A report of multicenter data from a web-based registry.
    Palepu J; Shrikhande SV; Bhaduri D; Shah RC; Sirohi B; Chhabra V; Dhar P; Sastry R; Sikora S
    Indian J Gastroenterol; 2017 Nov; 36(6):445-451. PubMed ID: 29457213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
    Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
    Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic factors and long-term outcome of pancreatic neuroendocrine neoplasms: Ki-67 index shows a greater impact on survival than disease stage. The large experience of the Spanish National Tumor Registry (RGETNE).
    Martin-Perez E; Capdevila J; Castellano D; Jimenez-Fonseca P; Salazar R; Beguiristain-Gomez A; Alonso-Orduña V; Martinez Del Prado P; Villabona-Artero C; Diaz-Perez JA; Monleon A; Marazuela M; Pachon V; Sastre-Valera J; Sevilla I; Castaño A; Garcia-Carbonero R
    Neuroendocrinology; 2013; 98(2):156-68. PubMed ID: 23988576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Best prognostic factor of neuroendocrine tumors: Grade or Stage? A multidisciplinary single-center study.
    Özaslan E; Bayram F; Karaca H; Gürsoy Ş; Öztürk F; Sözüer E; Abdurrezzak Ü; Yurci A; Can Sezgin G; Yıldırım A; Başpınar O; Kula M; Özkan M
    Turk J Gastroenterol; 2016 Nov; 27(6):509-514. PubMed ID: 27852541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroendocrine gastroenteropancreatic tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up.
    Oberg K; Jelic S;
    Ann Oncol; 2008 May; 19 Suppl 2():ii104-5. PubMed ID: 18456741
    [No Abstract]   [Full Text] [Related]  

  • 7. Natural history and outcome in Chinese patients with gastroenteropancreatic neuroendocrine tumours: - a 17-year retrospective analysis.
    Chan DT; Luk AO; So WY; Kong AP; Chow FC; Ma RC; Lo AW
    BMC Endocr Disord; 2016 Feb; 16():12. PubMed ID: 26911576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and clinical features of the ectopic ACTH syndrome in patients with gastroenteropancreatic and thoracic neuroendocrine tumors.
    Kamp K; Alwani RA; Korpershoek E; Franssen GJ; de Herder WW; Feelders RA
    Eur J Endocrinol; 2016 Mar; 174(3):271-80. PubMed ID: 26643855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Racial Differences in Gastroenteropancreatic Neuroendocrine Tumor Treatment and Survival in the United States.
    Kessel E; Naparst M; Alpert N; Diaz K; Ahn E; Wolin E; Taioli E; Kim MK
    Pancreas; 2021 Jan; 50(1):29-36. PubMed ID: 33370020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Gastroenteropancreatic neuroendocrine tumors: clinical characteristics, diagnosis and prognosis at Hospital Universitario Clínico San Carlos (Madrid)].
    de Miguel Novoa MP; Fernández Capel F; Redondo Sedano JV; Sellers Carrera M; Aranda Jiménez V; Ortiz Pereira P; Sastre Valera J; Ortega Medina L; Díaz Pérez JÁ
    Endocrinol Nutr; 2014 May; 61(5):234-41. PubMed ID: 24560439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thirteen-month registration of patients with gastroenteropancreatic endocrine tumours in France.
    Lombard-Bohas C; Mitry E; O'Toole D; Louvet C; Pillon D; Cadiot G; Borson-Chazot F; Aparicio T; Ducreux M; Lecomte T; Etienne PL; Cacheux W; Legoux JL; Seitz JF; Ruszniewski P; Chayvialle JA; Rougier P;
    Neuroendocrinology; 2009; 89(2):217-22. PubMed ID: 18719344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors.
    Pape UF; Jann H; Müller-Nordhorn J; Bockelbrink A; Berndt U; Willich SN; Koch M; Röcken C; Rindi G; Wiedenmann B
    Cancer; 2008 Jul; 113(2):256-65. PubMed ID: 18506737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gastroenteropancreatic neuroendocrine (carcinoid) tumors in children.
    Johnson PR
    Semin Pediatr Surg; 2014 Apr; 23(2):91-5. PubMed ID: 24931354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathologic characteristics and prognosis of gastroenteropancreatic neuroendocrine neoplasms: a multicenter study in South China.
    Fang C; Wang W; Zhang Y; Feng X; Sun J; Zeng Y; Chen Y; Li Y; Chen M; Zhou Z; Chen J
    Chin J Cancer; 2017 Jun; 36(1):51. PubMed ID: 28637502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent epidemiology of patients with gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NEN) in Japan: a population-based study.
    Masui T; Ito T; Komoto I; Uemoto S;
    BMC Cancer; 2020 Nov; 20(1):1104. PubMed ID: 33189127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chilean Registry for Neuroendocrine Tumors: A Latin American Perspective.
    Pinto MP; Muñoz Medel M; Carrillo D; Retamal IN; Bravo ML; Valenzuela Y; Nervi B; Sánchez C; Galindo H; Ibañez C; Peña J; Balmaceda C; Madrid J; Briones J; Torres J; Nilo F; Guarda FJ; Quintana JC; Orellana P; Mondaca S; Acevedo F; Vicentini D; Cordova-Delgado M; Owen GI; Garrido M
    Horm Cancer; 2019 Feb; 10(1):3-10. PubMed ID: 30465145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroendocrine tumors in children and young adults: rare or not so rare.
    Sarvida ME; O'Dorisio MS
    Endocrinol Metab Clin North Am; 2011 Mar; 40(1):65-80, vii. PubMed ID: 21349411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinico-morphological analysis of the neuroendocrine neoplasms of the gastroenteropancreatic system.
    Delektorskaya VV; Kozlov NA; Chemeris GY
    Klin Lab Diagn; 2013 Oct; (10):48-50, 10-3. PubMed ID: 24640093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiologic Trends of and Factors Associated With Overall Survival for Patients With Gastroenteropancreatic Neuroendocrine Tumors in the United States.
    Xu Z; Wang L; Dai S; Chen M; Li F; Sun J; Luo F
    JAMA Netw Open; 2021 Sep; 4(9):e2124750. PubMed ID: 34554237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Localized high-grade gastroenteropancreatic neuroendocrine tumors: Defining prognostic and therapeutic factors for a disease of increasing clinical significance.
    Mosquera C; Koutlas NJ; Fitzgerald TL
    Eur J Surg Oncol; 2016 Oct; 42(10):1471-7. PubMed ID: 27528467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.